You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(600196.SH):復宏漢霖就在研產品HLX10在特定區域及領域內授出獨家商業權 與Kalbe Genexine達成正式協議
格隆匯 09-30 18:50

格隆匯9月30日丨復星醫藥(600196.SH)公佈,2019年9月12日,公司控股子公司上海復宏漢霖生物技術股份有限公司(“復宏漢霖”)與PT Kalbe Genexine Biologics(“Kalbe Genexine”)簽訂《BindingTerm Sheet》,復宏漢霖就在研產品HLX10(即重組抗PD-1人源化單克隆抗體注射液)擬授予Kalbe Genexine在區域內(即菲律賓、印度尼西亞、馬來西亞、新加坡等10個國家,下同)及領域內(即:(1)首個適應症、(2)2個聯合療法適應症、(3)Kalbe Genexine依約可選擇的其他2個適應症,下同)獨家開展商業化(包括但不限於出口、進口、推廣、儲存、要約出售及銷售等商業化行為,下同)的權利及為該等商業化目的而享有相關知識產權的權利等。

2019年9月30日,復宏漢霖與Kalbe Genexine簽訂《Exclusive License Agreement》(“《許可協議》”),雙方就此次合作達成正式協議。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account